Protocol V compared aflibercept, laser and observation for centre-involved diabetic macular oedema with good visual acuity. At two years, immediate injections did not reduce vision loss significantly.
doi: 10.1001/jama.2019.5790A meta-analysis compared intravitreal ranibizumab with laser photocoagulation for diabetic macular oedema.
doi: 10.3389/fendo.2025.1608456PHOTON compared 8 mg aflibercept at extended intervals with standard 2 mg dosing every eight weeks.
doi: 10.1016/j.ophtha.2025.10.028A meta-analysis pooled prospective deep-learning studies from 23 countries.
doi: 10.1016/j.survophthal.2025.11.012